SG11202101502YA - Anti-gdf15 antibodies, compositions and methods of use - Google Patents

Anti-gdf15 antibodies, compositions and methods of use

Info

Publication number
SG11202101502YA
SG11202101502YA SG11202101502YA SG11202101502YA SG11202101502YA SG 11202101502Y A SG11202101502Y A SG 11202101502YA SG 11202101502Y A SG11202101502Y A SG 11202101502YA SG 11202101502Y A SG11202101502Y A SG 11202101502YA SG 11202101502Y A SG11202101502Y A SG 11202101502YA
Authority
SG
Singapore
Prior art keywords
compositions
methods
gdf15 antibodies
gdf15
antibodies
Prior art date
Application number
SG11202101502YA
Inventor
Kevin Charles Beaumont
Danna M Breen
Jeffrey Raymond Chabot
Tao He
Ksenya Shchors
James R Apgar
Matthew Allister Lambert
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SG11202101502YA publication Critical patent/SG11202101502YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11202101502YA 2018-08-20 2019-08-15 Anti-gdf15 antibodies, compositions and methods of use SG11202101502YA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862765289P 2018-08-20 2018-08-20
US201862750393P 2018-10-25 2018-10-25
US201862750479P 2018-10-25 2018-10-25
US201962881064P 2019-07-31 2019-07-31
PCT/IB2019/056932 WO2020039321A2 (en) 2018-08-20 2019-08-15 Anti-gdf15 antibodies, compositions and methods of use

Publications (1)

Publication Number Publication Date
SG11202101502YA true SG11202101502YA (en) 2021-03-30

Family

ID=69232873

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202101502YA SG11202101502YA (en) 2018-08-20 2019-08-15 Anti-gdf15 antibodies, compositions and methods of use

Country Status (16)

Country Link
US (2) US11566066B2 (en)
EP (1) EP3841121A2 (en)
JP (2) JP7155403B2 (en)
KR (1) KR20210049840A (en)
CN (1) CN112912395A (en)
AU (1) AU2019323790A1 (en)
BR (1) BR112021003173A2 (en)
CA (1) CA3109905A1 (en)
CO (1) CO2021001893A2 (en)
IL (1) IL280963A (en)
MX (1) MX2021001841A (en)
PE (1) PE20211412A1 (en)
PH (1) PH12021550337A1 (en)
SG (1) SG11202101502YA (en)
TW (1) TWI803682B (en)
WO (1) WO2020039321A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2900263B1 (en) 2012-09-26 2019-06-05 Julius-Maximilians-Universität Würzburg Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
US11464856B2 (en) 2015-10-02 2022-10-11 Julius-Maximilians-Universität Würzburg Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15) and immune checkpoint blockers
CN112912395A (en) 2018-08-20 2021-06-04 辉瑞公司 anti-GDF 15 antibodies, compositions, and methods of use
US20230212274A1 (en) * 2020-02-21 2023-07-06 The Children's Medical Center Corporation Method for treating asthma or allergic disease
CN115968285A (en) * 2020-03-18 2023-04-14 Gmp生物技术有限公司 TGF-beta inhibition, agents and compositions therefor
US20230338396A1 (en) * 2020-05-14 2023-10-26 Augusta University Research Institute, Inc. Cannabidiol as a therapeutic modality for covid-19
JPWO2022092326A1 (en) * 2020-10-30 2022-05-05
IL302646A (en) * 2020-11-10 2023-07-01 Catalym Gmbh Anti-gdf15 antibody and a dosage regimen for the treatment of cancer
TWI839729B (en) * 2021-05-07 2024-04-21 大陸商信達生物製藥（蘇州）有限公司 Fc MUTANTS WITH MODIFIED BINDING CAPACITY TO Fc RECEPTORS
WO2022255401A1 (en) * 2021-06-03 2022-12-08 国立大学法人 東京大学 Disease marker expressed in association with abnormal erk-mapk pathway activation
CA3228576A1 (en) * 2021-08-10 2023-02-16 Byomass Inc. Anti-gdf15 antibodies, compositions and uses thereof
WO2023039359A1 (en) * 2021-09-10 2023-03-16 Ngm Biopharmaceuticals, Inc. Methods of treating cancer and tumor-related weight loss and cachexia
WO2023048425A1 (en) * 2021-09-24 2023-03-30 재단법인대구경북과학기술원 Gfral-antagonistic antibody having improved affinity, and use thereof
WO2023079430A1 (en) * 2021-11-02 2023-05-11 Pfizer Inc. Methods of treating mitochondrial myopathies using anti-gdf15 antibodies
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
WO2023141815A1 (en) * 2022-01-26 2023-08-03 康源博创生物科技(北京)有限公司 Antibody molecule against growth and differentiation factor 15 and use thereof
WO2023217068A1 (en) * 2022-05-09 2023-11-16 舒泰神（北京）生物制药股份有限公司 Antibody that specifically recognizes gdf15 and use thereof
CN116444667B (en) * 2023-06-13 2023-09-01 上海驯鹿生物技术有限公司 GDF 15-targeted fully-humanized antibody and application thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
AR039067A1 (en) 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
AU2002357060A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Antibody categorization based on binding characteristics
CN102746399B (en) 2002-12-24 2016-03-02 里纳特神经***学公司 Anti-ngf antibodies and using method thereof
EP2774620A1 (en) 2004-04-13 2014-09-10 St Vincent's Hospital Sydney Limited Method for modulating weight loss
EP2783698A1 (en) 2007-08-16 2014-10-01 St Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (MIC-1) activity
EP2324055A2 (en) 2008-08-25 2011-05-25 Amplimmune, Inc. Pd-1 antagonists and methods of use thereof
JP2013512251A (en) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Simultaneous inhibition of PD-L1 / PD-L2
MY166429A (en) * 2010-11-17 2018-06-26 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
SG11201402603WA (en) 2011-11-28 2014-06-27 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
US9175076B2 (en) * 2012-12-21 2015-11-03 Aveo Pharmaceuticals, Inc. Anti-GDF15 antibodies
JP6865585B2 (en) * 2014-03-26 2021-04-28 ユリウス・マクシミリアンス−ウニヴェルジテート・ヴュルツブルクＪｕｌｉｕｓ Ｍａｘｉｍｉｌｉａｎｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｗｕｅｒｚｂｕｒｇ Monoclonal antibody against growth differentiation factor 15 (GDF-15) and its use for treating cancer cachexia and cancer
US20170137505A1 (en) 2014-06-20 2017-05-18 Aveo Pharmaceuticals, Inc. Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator
DK3197493T3 (en) 2014-09-25 2021-05-31 Aveo Pharmaceuticals Inc PROCEDURES FOR CONVERSION OF COACHE AND EXTENSION OF SURVIVAL INCLUDING ADMINISTRATION OF A GDF15 MODULATOR AND AN ANTI-CANCER
TWI595006B (en) 2014-12-09 2017-08-11 禮納特神經系統科學公司 Anti-pd-1 antibodies and methods of use thereof
US10647756B2 (en) 2015-05-18 2020-05-12 Pfizer Inc. Humanized antibodies
CN112912395A (en) * 2018-08-20 2021-06-04 辉瑞公司 anti-GDF 15 antibodies, compositions, and methods of use

Also Published As

Publication number Publication date
PH12021550337A1 (en) 2021-10-04
KR20210049840A (en) 2021-05-06
US20200055930A1 (en) 2020-02-20
WO2020039321A3 (en) 2020-05-07
US20220380448A1 (en) 2022-12-01
IL280963A (en) 2021-04-29
CA3109905A1 (en) 2020-02-27
TWI803682B (en) 2023-06-01
MX2021001841A (en) 2021-05-13
US11566066B2 (en) 2023-01-31
CN112912395A (en) 2021-06-04
TW202021619A (en) 2020-06-16
JP2022188191A (en) 2022-12-20
EP3841121A2 (en) 2021-06-30
JP7155403B2 (en) 2022-10-18
CO2021001893A2 (en) 2021-03-08
JP2021526847A (en) 2021-10-11
BR112021003173A2 (en) 2021-05-11
AU2019323790A1 (en) 2021-03-11
WO2020039321A2 (en) 2020-02-27
PE20211412A1 (en) 2021-08-02
WO2020039321A8 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
IL280963A (en) Anti-gdf15 antibodies, compositions and methods of use
IL272367A (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
IL276731A (en) Anti-cd73 antibodies and methods of use thereof
ZA202102034B (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
IL278821A (en) Anti-sirpa antibodies and methods of use thereof
SG11202010909RA (en) Anti-msr1 antibodies and methods of use thereof
IL283754A (en) Anti-claudin antibodies, compositions comprising same and uses thereof
IL270214A (en) Anti-sortilin antibodies and methods of use thereof
IL280317A (en) Anti-avb8 antibodies and compositions and uses thereof
IL277212A (en) Anti-klk5 antibodies and methods of use
IL279648A (en) Anti-sirp-beta1 antibodies and methods of use thereof
EP3720481A4 (en) Anti-dclk1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof
SG11202011227VA (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
IL283884A (en) Anti-il-36 antibodies and methods of use thereof
IL282939A (en) Mixtures and compositions comprising 5-fluoro-4-imino-3- methyl-1-tosyl-3,4- dihydropyrimidin-2-one, and methods of use thereof
IL280338A (en) Anti-siglec-5 antibodies and methods of use thereof
IL280280A (en) Compositions of fcrn antibodies and methods of use thereof
IL277786A (en) Aav compositions, methods of making and methods of use
SG11202011041YA (en) Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof
IL279227A (en) Anti-siglec-7 antibodies and methods of use thereof
EP3735246A4 (en) Mito-lonidamine, compositions and methods of use
GB201800461D0 (en) Novel combination and use of antibodies
GB201800395D0 (en) Novel combination and use of antibodies